Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
Kevin A. Hay(Occupational Cancer Research Centre), Cameron J. Turtle(The University of Sydney)
Cited by 399
Related Papers
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
|Blood|2017|1.1k
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
|Blood|2016|743
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
|Nature Biotechnology|2017|623
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
|Blood|2017|564
Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARs
|Journal for ImmunoTherapy of Cancer|2025|1